REGN Stock: Constructive Developments Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported earnings on May 4, 2017, and although it missed on the bottom line, REGN stock is still surging higher by 5.51% on the back of a positive reinforcement of forward guidance. I have been starting to focus on biotechnology stocks as of late, because I have an inclination to believe that the lagging performance that has plagued this sector is soon going to be a thing of the past, and this sector is going to pl...
REGN Stock: Constructive Developments Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported earnings on May 4, 2017, and although it missed on the bottom line, REGN stock is still surging higher by 5.51% on the back of a positive reinforcement of forward guidance. I have been starting to focus on biotechnology stocks as of late, because I have an inclination to believe that the lagging performance that has plagued this sector is soon going to be a thing of the past, and this sector is going to pl...
Share this Article
Recommended